People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These are pills that are taken by mouth. This type of pill is called "Bruton Tyrosine Kinase Inhibitor" or BTKi. Another treatment for CLL/SLL is a different pill called venetoclax.
The purpose of this study is to compare continuing the current treatment with BTKi alone, as long as it is working, to another arm of treatment which adds venetoclax to the current treatment (BTKi), for one year. After one year, both pills in this arm of treatment would be stopped and the participants will be closely monitored.

开始日期2025-01-01

申办/合作机构

VA Office of Research and Development

NCT06441097 / Not yet recruiting临床2期IIT

A Study to Evaluate the Efficacy and Safety of Genotype-guided Targeted Agents in Combination With POLA-RCHP VERSUS POLA-RCHP in Patients With Previously Untreated Diffuse Large B-cell Lymphoma

The purpose of this study is to compare the efficacy and safety of genotype-guided targeted agents in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola RCHP-X) versus Pola RCHP in Chinese patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

开始日期2024-12-31

申办/合作机构

上海交通大学医学院附属瑞金医院

NCT06054776 / Recruiting临床2期IIT

A Phase 2 Study of Glofitamab With Acalabrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

This phase II trial studies the side effects of acalabrutinib, obinutuzumab, and glofitamab and how well they work together for treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Glofitamab is a class of medications called bispecific antibodies. Bispecific antibodies are designed to simultaneously bind to T cells and cancer cell antigens, leading to T-cell activation, proliferation, and cancer cell death. Giving acalabrutinib, obinutuzumab, and glofitamab together may be a safe and effective treatment for patients with relapsed or refractory mantle cell lymphoma.

开始日期2024-12-10

申办/合作机构

City of Hope National Medical Center

[+1]

100 项与阿可替尼相关的临床结果

登录后查看更多信息

100 项与阿可替尼相关的转化医学

登录后查看更多信息

100 项与阿可替尼相关的专利（医药）

登录后查看更多信息

481

项与阿可替尼相关的文献（医药）

2024-12-01·Journal of Pharmacy Practice

CNS Aspergillosis and Cryptococcosis with Cytomegalovirus Pneumonia in a Patient with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Article

作者: Sassine, Joseph ; Siegrist, Emily A. ; White, Bryan P. ; Shibib, Dena ; Fallin, Taylor ; Sahra, Syeda ; Summers, Katherine ; Thacker, Erica

Bruton’s tyrosine kinase inhibitors (BTKis) are the preferred treatment for chronic lymphocytic leukemia (CLL). Despite their therapeutic benefits, these targeted agents have been associated with an increased risk of invasive infections. We describe a 68-year-old male who developed multiple bacterial, fungal and viral infections while on treatment with acalabrutinib. To our knowledge, this is the first reported case of concomitant CNS infections with Cryptococcus neoformans and Aspergillus fumigatus, along with cytomegalovirus (CMV) and herpes simplex virus type 1 (HSV-1) pneumonia while on acalabrutinib. This case adds to the scarce literature of fungal and bacterial infections associated with acalabrutinib, raising the suspicion that infection risk is a medication class effect for BTKis.

2024-11-01·Bulletin du Cancer

Effets indésirables cardiovasculaires sous inhibiteurs de la Bruton tyrosine kinase : mécanismes physiopathologiques, dépistage et prise en charge

Review

作者: Inchiappa, Luca ; Stocker, Nicolas ; Goncalves, Trecy ; Tchernonog, Emmanuelle ; Croizier, Carolyne ; Cautela, Jennifer

The covalent Bruton tyrosine kinase inhibitors (iBTKs) have profoundly transformed the management of B-cell lymphoid malignancies, particularly chronic lymphocytic leukemia (CLL). These targeted therapies, with ibrutinib as the pioneer, have paved the way for significant improvement in the prognosis of many patients. With second-generation iBTKs such as acalabrutinib and zanubrutinib, the therapeutic landscape has expanded, offering potential new options for patients with CLL. This review focuses on the cardiovascular adverse effects associated with these treatments. It delves into the underlying pathophysiological mechanisms of these effects, highlighting the complex interactions between these molecules and the cardiovascular system. Additionally, it examines the frequency of adverse effects according to the type of iBTK, drawing on data from clinical trials and real-world clinical practice. Finally, the importance of close cardio-oncological monitoring is emphasized, with essential collaboration between hematologists and cardiologists. Strategies for screening and managing cardiovascular adverse effects are also discussed, emphasizing the need for a proactive approach in managing these complications. Experts propose a pragmatic follow-up of these patients, through a central illustration and a figure adapted from European cardio-oncology guidelines, to simplify hematologists' practice.

2024-11-01·Annals of Hematology

Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis

Article

作者: Baiocchi, Otavio Cesar Carvalho Guimarães ; Nunes, Rafael Amorim Belo ; de Oliveira Marques, Mariana ; Bachour, Philip ; Avezum, Álvaro

Bruton tyrosine kinase (BTK) inhibitors play an important role in targeted treatment of B-cell lymphoproliferative disorders. However, adverse events may limit the proper course of treatment in many patients. The purpose of this study is to compare the risk of cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia (CLL) or small cell lymphocytic lymphoma (SLL) treated with the first-generation BTK inhibitor ibrutinib versus second-generation acalabrutinib, using real-world data from a collaborative multinational network. We used data from the network (TriNetX), which encompasses more than 100 healthcare organizations worldwide. We queried the database for patients aged ≥ 18 years with chronic lymphocytic leukemia or small-cell lymphomas treated with ibrutinib or acalabrutinib in the past ten years before the analysis. We used propensity score matching to balance the cohorts. The 3-year cumulative incidences and hazard ratios for the following outcomes were calculated: atrial flutter or fibrillation, other arrhythmias, heart failure, ischemic stroke or peripheral embolism, acute coronary syndrome, bleeding, and sepsis. We compared 2,107 patients in each group. Atrial fibrillation or flutter occurred in 150 (7.1%) patients with acalabrutinib and 310 (14.7%) patients with ibrutinib during the 3-year follow-up (hazard ratio, 0.68, 95% CI 0.55-0.84). New-onset hypertension occurred in 342 (16.3%) patients in the acalabrutinib group and 584 (27.7%) patients in the ibrutinib group (hazard ratio 0.81, 95% CI 0.66-0.98). Sepsis was diagnosed in 136 (6.5%) patients in the acalabrutinib group versus 239 (11.3%) patients in the ibrutinib group (hazard ratio 0.77, 95 CI 0.60-0.98). The two groups had no significant differences concerning the other adverse events. In a large retrospective cohort using real-world data from electronic medical registers, patients with CLL or SLL treated with acalabrutinib had a better cardiovascular and non-cardiovascular safety profile than those treated with ibrutinib, with lower risks of atrial flutter or fibrillation, new-onset arterial hypertension, and sepsis.

499

项与阿可替尼相关的新闻（医药）

2024-11-19

·健识局

亚盛医药血液肿瘤创新药上市申请获受理

近日，港股创新药公司亚盛医药宣布，其核心产品Bcl-2抑制剂APG-2575的上市申请已获国家药品监督管理局（NMPA）新药审评中心（CDE）受理。据悉，全球仅有艾伯维的Bcl-2抑制剂维奈克拉获批上市，在CLL/SLL治疗领域尚未有任何一款Bcl-2抑制剂在中国获批。此次亚盛医药的APG-2575这是首个在国内提交NDA的国产原研Bcl-2抑制剂，也意味着APG-2575有望成为全球第二个获批的Bcl-2抑制剂，同时也是国内首个针对CLL/SLL适应症获批的Bcl-2抑制剂。 Bcl-2是一种细胞凋亡抑制因子，在许多恶性血液肿瘤特别是CLL/SLL中过度表达，是癌细胞逃避凋亡的重要机制之一。因此，靶向并抑制Bcl-2蛋白一度成为了癌症治疗的热门研究策略；Bcl-2也自然成了理想的药物作用靶点。目前，APG-2575正在开展多项注册III期临床试验，分别为联合BTKi治疗经治CLL/SLL患者的全球注册III期临床试验（由美国FDA许可）；联合阿可替尼一线治疗初治CLL/SLL患者的全球注册III期临床试验；联合阿扎胞苷（AZA）一线治疗新诊断老年或不耐受标准化疗的急性髓系白血病（AML）的全球注册III期临床试验；联合AZA一线治疗新诊断中高危骨髓增生异常综合征（MDS）患者的全球注册III期临床试验。随着未来更多适应症的探索与获批，APG-2575将为全球血液肿瘤患者带去新的治疗选择。运营｜廿十三国家医保局与40多家龙头企业开会，释放了什么信号？ 4.8亿挂牌拍卖，民营医院撑不住了新事 | 媒体称强生中国区开始裁员

临床3期申请上市

2024-11-19

·药智网

165亿大药，国产首款获批在即

目前，全球只有一款Bcl-2抑制剂——维奈克拉获批上市，由艾伯维和罗氏联合开发。艾伯维财报显示，2023年维奈克拉收入达22.8亿美元（约合人民币165亿元），同比增长13.9%。如此诱人的黄金大单品，国产首款也即将迎来突破。近日，亚盛医药发布公告，其自主研发的新型选择性Bcl-2抑制剂APG-2575的新药上市申请(NDA)已获CDE受理，并被推荐纳入优先审评程序，用于治疗难治或复发性(r/r)慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)。这是首个在国内提交NDA的国产原研Bcl-2抑制剂，有望成为全球第二个上市的Bcl-2抑制剂。 165亿大药，国产首款正加速撞线。 >01< BTK抑制剂的“最强后盾” 目前全球有6款BTK抑制剂获批上市，包括第一代共价抑制剂伊布替尼，第二代共价抑制剂阿可替尼、泽布替尼、tirabrutinib和奥布替尼以及第三代非共价抑制剂pirtobrutinib，它们在血液瘤如慢性淋巴细胞白血病（CLL）和套细胞淋巴瘤（MCL）等取得巨大成功，尤其是伊布替尼，其由于上市时间早销售额遥遥领先，2021年市场销售额曾达到97.8亿美元。然而由于长时间连续给药，BTK抑制剂容易引起BTK蛋白突变从而导致其耐药性和不可接受的毒性。 B细胞淋巴瘤-2（Bcl-2）是一种在血液肿瘤中高表达的关键细胞凋亡调节蛋白，Bcl-2抑制剂可以特异性结合BCL-2，阻断其抑制细胞凋亡的功能，从而触发肿瘤细胞的程序性死亡（凋亡），达到治疗目的。维奈克拉是全球首款且唯一获批的Bcl-2抑制剂，多项临床研究显示维奈克拉与伊布替尼联合用药的优异疗效。在2期探索维奈克拉与伊布替尼一线治疗CLL的疗效的CAPTIVATE试验中，维奈克拉与伊布替尼组达到其完全缓解（CR）率的主要终点，在缺失17p患者的CR率为56%，显著高于预先设定的37%最低率。在所有接受治疗的人群中，CR率为55%，24个月PFS和OS率分别为95%和98%。在针对一线治疗CLL/SLL固定疗程维奈克拉与伊布替尼的随机对照临床GLOW研究中，维奈克拉与伊布替尼组的PFS显著长于苯丁酸氮芥-奥妥珠单抗组（风险比，0.216）。 2022年8月4日，欧盟委员会基于上述临床结果批准扩大维奈克拉与伊布替尼联合一线治疗CLL成人患者。维奈克拉与伊布替尼的强强联合，不仅进一步提高维奈克拉的销售额，维奈克拉2022年销售额同比增长10.4%至20.1亿美元，2023年销售额同比增长13.9%至22.88亿美元，而且也缓解了伊布替尼由于专利到期以及其他几代BTK抑制剂的竞争而导致的销售额急剧下降，加强了艾伯维在肿瘤领域的竞争。维奈克拉是由艾伯维研发的首款获FDA批准上市的Bcl-2抑制剂，于2016年4月11日在美国上市，随后2020年12月，维奈克拉在国内获批上市。目前，维奈克拉已获批多个适应症，包括单药或联合Rituxan治疗存在17p删除突变且既往已接受至少一种疗法的CLL患者，联合一种低甲基化剂或低剂量阿糖胞苷（LD-AC）一线治疗新确诊的年龄在75岁及以上的老年急性髓性白血病（AML）患者以及联合奥比妥珠单抗治疗先前没有接受过治疗的CLL成人患者等。除此之外，维奈克拉在临床上开展多项实验，包括以确定cirmtuzumab巩固治疗维奈克拉可测量疾病患者的疗效的2期研究（NCT04501939），维奈克拉联合奥妥珠单抗和伊布替尼治疗复发、难治性或既往未治疗的CLL患者的1b/2期研究（NCT02427451），评估口服维奈克拉片剂治疗19岁以上AML参与者不良事件和疾病活动变化的研究（NCT04826523）以及维奈克拉、奥妥珠单抗联合伊布替尼在复发/难治性套细胞淋巴瘤患者中的试验（OAsIs，NCT02558816）等。 >02< Bcl-2抑制剂在研进展如何？除了已上市的维奈克拉外，全球有多款在研的Bcl-2抑制剂，包括APG-2575、Sonrotoclax、ICP-248、TQB3909和S65487等（下表1）。表1 部分在研的Bcl-2抑制剂数据来源：公开资料整理 APG-2575是由亚盛医药研发的全球第二个、中国首个看到明确疗效、并进入关键注册临床阶段的Bcl-2抑制剂。与艾伯维策略类似，亚盛也在开发联合疗法，其APG-2575与阿斯利康的第二代BTK共价抑制剂阿可替尼联合治疗临床3期实验于2023年10月13日获得NMPA药物审评中心（CDE）临床试验许可，用于初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者一线治疗。 APG-2575的多项临床研究数据亮相国际会议，如2022ASH和2023 AACR会上公布了APG-2575联合阿可替尼在复发/难治（R/R）CLL/SLL患者中的客观反应率（ORR）达98%、在初治CLL/SLL患者中的ORR达100%，且保持了与单药治疗相当的良好安全性；在今年ASCO年会上，APG-2575联合阿扎胞苷治疗初治或复发/难治（R/R）急性髓系白血病（AML）患者的一项2期临床研究数据显示，在老年（≥75岁）或一般状况不佳（unfit）的初治AML患者中（n=39），ORR为64.1%，复合完全缓解率（CRc=CR+CRi）为51.3%。 Sonrotoclax是百济神州开发的一款强效、高选择性Bcl-2抑制剂，是继泽布替尼之后又一款重磅血液瘤药物。泽布替尼曾在临床上头对头打败了艾伯维的伊布替尼，是百济神州的一款重磅药物，泽布替尼2024年前三季度全球销售额超18亿美元，今年突破20亿美元已无悬念。 Sonrotoclax和泽布替尼联合治疗初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（TN-CLL/SLL）患者的一项临床1/2期试验显示具有良好的耐受性并达到深度反应。共有56例患者进行了反应评估。ORR为100%。在所有剂量中，CR率随着时间的推移而增加，总体CR中位时间为10.1个月。两个队列均未报告进展。去年10月，百济神州启动了一项开放标签、随机对照3期研究（NCT06073821），旨在评估Sonrotoclax联用泽布替尼对比维奈克拉联用奥妥珠单抗治疗CLL的疗效与安全性。今年ASCO会议上，Mazyar等人介绍了一项旨在比较Sonrotoclax联用泽布替尼对比维奈克拉联用奥妥珠单抗在TN CLL患者中的疗效3期试验设计方案。该研究方案如下：大约640名患者将按1：1的比例随机接受3个周期的泽布替尼单一疗法（每日总剂量320 mg，口服），然后接受sonrotoclax+泽布替尼12个周期，或标准维奈克拉+奥妥珠单抗治疗12个周期。主要终点是独立审查委员会（IRC）根据2018年iwCLL指南评估的PFS。 ICP-248是由诺诚健华研发的一款新型口服高选择性Bcl-2抑制剂，旨在单药或联合治疗各种恶性血液肿瘤。去年ASH会议上，ICP-248治疗复发或难治性B细胞恶性肿瘤患者的初步临床1/2期研究结果展示了良好的安全性和有效性。研究显示：ICP-248具有良好的生物利用度及PK分布，药物暴露与给药剂量呈现清晰的线性关系。未观察到剂量限制性毒性（DLT），无药物相关的不良事件直接导致的剂量中断及剂量减低。研究未观察到肿瘤溶解综合征（TLS），包括实验室TLS。今年1月份，ICP-248获FDA批准开展临床研究。 TQB3909是由正大天晴研发的一款BCL-2抑制剂，在今年ESMO会议上，研究人员以口头报告的形式首次公布了TQB3909的1期临床研究结果。研究结果显示：TQB3909治疗R/R CLL/SLL患者ORR为88.9%，完全缓解/完全缓解伴不完全血液学恢复（CR/CRi）为44.4%；对BTK抑制剂耐药的R/R CLL/SLL患者的ORR为83.3%，CR/CRi为41.7%。 TQB3909在临床上开展多项相关的研究，近期又获批两项新的临床试验默示许可，拟联合化疗用于急性淋巴细胞白血病（ALL）患者的治疗。 >03< 结语 Bcl-2抑制剂的赛道逐渐火热起来，加入布局的企业越来越多，目前仍无国产Bcl-2抑制剂获批上市。近期，亚盛医药的APG-2575的上市申请获CDE受理，用于治疗难治或复发性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者，有望成为全球第二款、国产第一款获批上市的Bcl-2抑制剂。参考文献 1.Constantine S Tam et.al,Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL:primary analysis of the CAPTIVATE FD cohort,Blood.2022 Feb 25;139(22):3278–3289 2.Combination Treatment with Sonrotoclax(BGB-11417),a Second-Generation BCL2 Inhibitor,and Zanubrutinib,a Bruton Tyrosine Kinase(BTK)Inhibitor,Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(TN-CLL/SLL):Data from an Ongoing Phase 1/2 Study 3.CELESTIAL-TNCLL:An ongoing,open-label,multiregional,phase 3 study of sonrotoclax(BGB-11417)+zanubrutinib vs venetoclax+obinutuzumab for treatmentna¨ıve(TN)CLL. 声明：本内容仅用作医药行业信息传播，为作者独立观点，不代表药智网立场。如需转载，请务必注明文章作者和来源。对本文有异议或投诉，请联系maxuelian@yaozh.com。责任编辑 | 史蒂文转载开白 | 马老师 18996384680（同微信）商务合作 | 王存星 19922864877（同微信）阅读原文，是受欢迎的文章哦

优先审批财报专利到期申请上市

2024-11-19

·Pharma CMC

亚盛医药「力胜克拉片」申报上市，并纳入优先审评

11月17日，亚盛医药发布公告，其自主研发的新型选择性Bcl-2抑制剂APG-2575（拟定中文通用名：力胜克拉片）的新药上市申请(NDA)已获CDE受理，并被推荐纳入优先审评程序，用于治疗难治或复发性(r/r)慢性淋巴细胞白血病╱小淋巴细胞淋巴瘤(CLL/SLL)。这是首个在国内提交NDA的国产原研Bcl-2抑制剂，有望成为全球第二个上市的Bcl-2抑制剂。此次提交的NDA是基于一项在中国开展的关键注册II期临床研究(APG2575CC201)结果。该研究旨在评估APG-2575单药治疗r/rCLL/SLL患者的有效性和安全性，该研究的主要终点指标为总缓解率(ORR)。 APG-2575是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制Bcl-2蛋白，恢复肿瘤细胞的正常凋亡过程，从而达到治疗肿瘤的目的。APG2575是全球第二个、中国首个看到明确疗效、并进入关键注册临床阶段的Bcl-2抑制剂，在多种血液肿瘤和实体瘤治疗领域具备广阔的治疗前景，特别在CLL/SLL患者中具有单药和联合治疗潜力。APG-2575在全球层面具同类最佳(Best-in-class)潜力，有望成为更安全、有效，且便捷的治疗选择。同时，APG-2575正在开展多项注册III期临床试验，分别为联合BTKi治疗经治CLL/SLL患者的全球注册III期临床试验（由美国FDA许可）；联合阿可替尼一线治疗初治CLL/SLL患者的全球注册III期临床研究；联合阿扎胞苷(AZA)一线治疗新诊断老年或不耐受标准化疗的急性髓系白血病(AML)的全球注册III期临床试验；联合AZA一线治疗新诊断中高危骨髓增生异常综合征(MDS)患者的全球注册III期临床试验。内容来源于网络，如有侵权，请联系删除。

申请上市优先审批

100 项与阿可替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10893	阿可替尼	L01XE51	DB11703

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
小淋巴细胞淋巴瘤	美国	AstraZeneca UK Ltd.	2019-11-21
慢性淋巴细胞白血病	加拿大	AstraZeneca Canada, Inc.	2019-10-02
套细胞淋巴瘤	美国	AstraZeneca UK Ltd.	2017-10-31

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
套细胞淋巴瘤	临床3期	中国香港	AstraZeneca PLC	2017-04-05
套细胞淋巴瘤	临床3期	越南	AstraZeneca PLC	2017-04-05
慢性淋巴细胞白血病	临床3期	哥伦比亚	Acerta Pharma BV	2015-06-26
慢性淋巴细胞白血病	临床3期	以色列	Acerta Pharma BV	2015-06-26
慢性淋巴细胞白血病	临床3期	智利	Acerta Pharma BV	2015-06-26
慢性淋巴细胞白血病	临床3期	巴西	Acerta Pharma BV	2015-06-26
慢性淋巴细胞白血病	临床3期	新西兰	Acerta Pharma BV	2015-06-26
难治性套细胞淋巴瘤	临床1期	-	Acerta Pharma BV	2016-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04215809 (ASH2024) 人工标引	临床1期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤	176	APG-2575	(選憲鬱鏇夢淵壓鑰廠簾) = Incidence and severity of TEAEs were similar across cohorts. Common (>10%) any-grade TEAEs in all cohorts combined were neutropenia (59 [33.5%]), diarrhea (38 [21.6%]), anemia (27 [15.3%]), and thrombocytopenia (26 [14.8%]). 簾壓襯夢繭衊鏇選簾艱 (蓋簾選網夢築願夢鏇選 ) 更多	积极	2024-12-09
				APG-2575+Acalabrutinib
ASH2024	N/A	套细胞淋巴瘤	-	Acalabrutinib 100 mg BID + Rituximab 375 mg/m2 IV	積鑰憲膚繭蓋鑰襯艱壓(構觸憲顧餘鹹構遞壓夢) = grade 3-4 AE were cardiovascular toxicity in 7 pts 鏇繭積觸構遞築積廠範 (齋齋鏇願鬱鏇壓積糧齋 ) 更多	-	2024-12-09
NCT04462328 (985Phase I, ASH2024)	临床1期	原发性中枢神经系统淋巴瘤 Bruton tyrosine kinase inhibitors \| immune checkpoint inhibitors	13	Acalabrutinib 100 mg BID + Durvalumab 1500 mg IV	遞遞獵鹽繭窪窪壓範夢(廠糧糧廠鬱廠廠膚餘襯) = Treatment-related adverse events (AEs) of any grade occurred in 13 (100%) pts 鬱網襯積齋製窪襯壓築 (夢餘網壓觸鏇衊夢遞製 ) 更多	积极	2024-12-09
ASH2024	N/A	套细胞淋巴瘤	-	Acalabrutinib	壓獵範觸選鏇範廠繭鬱(衊蓋窪範齋壓構鑰糧醖) = 16% 鏇餘願夢衊鹹鬱鏇遞範 (觸製選獵鹽廠鹽構願選 ) 更多	-	2024-12-09
				Venetoclax
ASH2024	N/A	慢性淋巴细胞白血病	-	Acalabrutinib 100 mg	憲醖遞膚選築齋膚顧範(遞顧夢遞夢鑰構膚鑰襯) = AEs leading to death occurred in 1 pt in the acalabrutinib arm (unrelated to study drug) 遞製餘鹹構糧鏇遞繭築 (淵製鑰窪築窪廠憲糧憲 ) 更多	-	2024-12-08
				Chlorambucil+Rituximab
ASH2024	N/A	弥漫性大B细胞淋巴瘤	-	RICE-A + Acalabrutinib 100mg BID	窪觸願鏇憲築齋範醖範(襯鹹簾繭選憲廠餘願夢) = Gastrointestinal AEs were observed in 5 patients (4 Grade1/2 and 1 Grade3/4) 衊廠簾遞糧夢簾壓廠憲 (憲遞繭築製膚蓋餘糧積 ) 更多	-	2024-12-08
ASH2024	N/A	慢性淋巴细胞白血病	-	Ibrutinib 420 mg/day	製選遞窪鏇鏇鑰鹽壓夢(窪夢範艱鹹鬱蓋襯獵鹹) = 21% for acala 鹹淵蓋鹹構繭襯艱窪憲 (鹽願願餘觸獵鑰繭願糧 ) 更多	-	2024-12-08
				Acalabrutinib 100 mg twice daily
ASH2024	N/A	慢性淋巴细胞白血病	-	Acalabrutinib	(夢淵遞膚壓窪鬱衊艱膚) = 鏇構鬱顧鹽鹽餘獵選範網網窪選繭鹹衊蓋餘醖 (糧壓膚糧願製壓窪築築 ) 更多	-	2024-12-07
				Obinutuzumab	(襯遞顧顧範蓋蓋襯簾憲) = 觸艱繭窪衊艱鹹廠醖遞願齋製製齋壓觸憲齋製 (膚鏇網構夢選壓衊繭壓 ) 更多
ASH2024	N/A	套细胞淋巴瘤	-	Acalabrutinib (BR/CR)	築鏇獵醖鏇餘遞醖獵廠(衊襯窪襯遞製鏇築顧觸) = 築膚齋廠淵網膚壓顧壓選艱選淵範願鏇膚糧窪 (製積憲獵簾選夢糧廠繭 ) 更多	-	2024-12-07
				Acalabrutinib (BR/CR-A)	築鏇獵醖鏇餘遞醖獵廠(衊襯窪襯遞製鏇築顧觸) = 齋選餘鑰鑰蓋鬱構築鑰選艱選淵範願鏇膚糧窪 (製積憲獵簾選夢糧廠繭 ) 更多
ASH2024	N/A	套细胞淋巴瘤	-	Acalabrutinib plus bendamustine-rituximab (ABR)	(築餘網餘膚餘膚廠衊範) = 蓋醖窪構襯積淵夢餘醖鏇餘壓網膚艱簾齋艱餘 (繭醖繭廠範餘艱衊鬱糧 ) 更多	-	2024-12-07
				Placebo plus bendamustine-rituximab (PBR)	(築餘網餘膚餘膚廠衊範) = 繭積觸鏇醖鏇製齋繭鏇鏇餘壓網膚艱簾齋艱餘 (繭醖繭廠範餘艱衊鬱糧 ) 更多